Please provide your email address to receive an email when new articles are posted on . At 52 weeks, MASH resolution without worsening of fibrosis was reported among 36% on denifanstat vs. 13% on ...
Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of ...
Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...
Please provide your email address to receive an email when new articles are posted on . More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A ...
Shannon Bailey, Ph.D., Professor, Molecular and Cellular Pathology, Chair, UAB Institutional Animal Care and Use Committee (IACUC), has been awarded an R01 grant funding her research on circadian and ...
ACC, Acetyl-CoA Carboxylase; PPAR, peroxisome proliferator–activated receptor; MPC, mitochondrial pyruvate carrier; THR, thyroid hormone receptor; ASK-1, apoptosis signaling kinase-1; GLP-1R, glucagon ...
New research shows that Vitamin E therapy significantly enhances liver function and reduces inflammation in MASH patients, providing a safer and effective treatment option in the fight against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results